Subscribe to RSS
You must select a month AND year to filter.
Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism (VTE).
On January 17, 2012, the U. S. Food and Drug Administration approved glucarpidase injection (Voraxaze®, BTG International Inc.) for the treatment of toxic plasma methotrexate concentrations (> 1 μmol/L) in patients with delayed methotrexate clearance due to impaired renal function.
The U.S. Food and Drug Administration (FDA) is notifying the public that two additional cases of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection that can result in death, have been reported with the lymphoma drug Adcetris (brentuximab vedotin). Due to the serious nature of PML, a new Boxed Warning highlighting this risk has been added to the drug label.
< Prev Next > Page 1 of 144
Follow ASH on Twitter for up-to-date information.
Learn more about how hematologists help save lives in this hour-long documentary.
Access the latest issue of the Society's journal.
Read the latest issue for news in hematology.
View the new blood disease animations just added.